Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value

PURPOSE: Sunitinib—a multi-targeted tyrosine kinase inhibitor—can modulate circulating inflammatory factors in cancer patients that may be relevant for hepatocellular carcinoma (HCC) progression. However, a recent phase III study of sunitinib in HCC was halted due to its toxicity. Here, we studied t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Zhu, Andrew X., Duda, Dan G., Ancukiewicz, Marek, di Tomaso, Emmanuelle, Clark, Jeffrey W., Miksad, Rebecca, Fuchs, Charles S., Ryan, David P., Jain, Rakesh K.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3023846/
https://ncbi.nlm.nih.gov/pubmed/20843836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0515
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items